Basecamp Research raises $140M for AI therapeutics

Basecamp Research raised an oversubscribed $140 million Series C to train its EDEN biological models and advance AI-designed therapeutics toward clinical development. The company’s financing announcement says its Trillion Gene Atlas draws on data from more than 30 countries and that the pipeline remains preclinical. For builders, file this as a capital and data signal—not clinical proof—and watch trial milestones before treating biological foundation models as validated drug engines; OpenAI’s GPT Rosalind work on drug discovery offers a useful comparison point for AI-assisted discovery claims.